News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AVAX Technologies, Inc. (AVXT) Presents Results of a Dose-Response Study of MVax(R) at American Society of Clinical Oncology



6/3/2008 2:37:20 PM

PHILADELPHIA--(BUSINESS WIRE)--AVAX Technologies, Inc. (OTC Market: AVXT.OB) presented the results of its phase I-II trial of MVax®, its autologous, hapten-modified melanoma vaccine, at the annual meeting of the American Society for Clinical Oncology (ASCO) at a poster session held Sunday, June 1.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES